[Bone and Men's Health. Bisphosphonate therapy for prostate cancer].
Recently, prostate cancer is one of the common cancer in Japanese men, with a high incidence of bone metastasis. Bone metastasis is incurable and contributes significantly to disease-specific morbidity and mortality. And more, there are many opportunity to perform androgen deprivation therapy in prostate cancer patients, but worsen osteoporosis and raise a risk of bone fracture. Thus, the management of bone metabolism in patients is a clinically significant issue. The bisphosphonates are targeted to osteoclasts and are considered to be standard management in the care of bone metastasis patients in combination with chemotherapy and hormone therapy. In this review, we summarized the current understanding and therapy of bone metastasis in prostate cancer in mainly respect to Zoredronic acid use.
Suzuki
Hiroyoshi
H
Department of Urology, Chiba University Graduate School of Medicine.
Kamiya
Naoto
N
Yano
Masashi
M
Endo
Takumi
T
Takano
Makoto
M
Kawamura
Koji
K
Imamoto
Takashi
T
Ichikawa
Tomohiko
T
D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D005598:Fractures, Spontaneous / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid